
|Articles|January 3, 2019
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to a Diagnostic Assay for Non-Alcoholic SteatoHepatitis
Advertisement
LabCorp, a global life sciences company, and GENFIT, a late-stage biopharmaceutical company, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement hopes to expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement